157123-02-9Relevant academic research and scientific papers
New and scalable access to karrikin (KAR1) and evaluation of its potential application on corn germination
Lachia, Mathilde,Fonne-Pfister, Raymonde,Screpanti, Claudio,Rendine, Stefano,Renold, Peter,Witmer, David,Lumbroso, Alexandre,Godineau, Edouard,Hueber, Damien,De Mesmaeker, Alain
, (2018)
Karrikin (KAR1), also named ‘karrikinolide’, was isolated in 2004 from smoke water and identified as a very potent germination stimulant as well as controlling early seedling development for a large variety of plant species. We reported herein an unprecedented and scalable synthesis of Karrikin (KAR1) based on an elegant and efficient 6-endo-dig cyclization. Moreover, we evaluated the effect of KAR1 on corn seeds germination, we carried out additional studies on the uptake of this butenolide into corn seeds, and the main soil chemiodynamic properties (i.e., persistence and mobility) were calculated or estimated. Finally, we provided a rationalization of the experimental results by building a homology model of corn KAI2, using as template the X-ray of the KAI2 protein from Arabidopsis thaliana.
Palladium Catalysed Cross-Coupling of Vinyl Triflates with 9-Alkyl-9-borobicyclononanes. Total Synthesis of (-)-Isoseiridine.
Grigg, Ronald,Kennewell, Peter,Savic, Vladimir
, p. 5489 - 5494 (1994)
Pd(O) Catalysed cross-coupling of butenolide-3-triflates to 9-alkyl-9-borobicyclononanes occurs in moderate to good yield and tolerates a range of functionality.Application of this methodology combined with addition of diethylzinc to a butenolide aldehyde in the presence of an ephedrine derivative leads to a 3-step synthesis of (-)-isoseiridine with 88percent e.e. in good yield.
A synthetic approach to enfumafungin
Zorn, Nicolas,Lett, Robert
, p. 4325 - 4330 (2006)
The stereospecific synthesis of the dienophile subunits 5 was achieved from the butenolide 6. Ester 19 was obtained in 67% overall yield (2 steps), with no intermediate purification, by a sodium chlorite oxidation of the corresponding aldehyde in buffered
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2017/07/31)
The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylax
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2016/03/13)
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2016/02/05)
Compounds of Formula I and the pharmaceutically acceptable salts thereof are provided as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2016/05/19)
The present invention provides compounds of Formula I : (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and proph
INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2016/09/22)
Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2015/07/15)
Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2015/07/15)
Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.
